The Northeast Biodefense Center (NBC) is a consortium of >350 investigators in 28 academic and research institutions (many of them in close proximity to one another in the greater NYC metro area), and 13 US based governmental and international organizations. Over the past 5 years, NBC investigators have demonstrated their commitment to working together across disciplines and institutional boundaries in research and training programs focused on biodefense and emerging infectious diseases as well as emergency preparedness. Evidence of productivity includes >160 publications, 15 invention disclosures, 13 patent applications and 5 licenses for product development. This renewal will comprise 42 investigators and 32 research projects organized into 6 scientific theme areas: Passive Immunotherapeutics (chair: Arturo Casadevall, Einstein);Vaccines (chair: John Rose, Yale);Diagnostics and Pathogen Discovery (chair: Ian Lipkin, Columbia);Therapeutics (chairs: Charles Rice, Rockefeller and Howard Shuman, Columbia,);Innate Immunity (chairs: David Levy, NYU, and Adolfo Garcia-Sastre, Sinai), and Microbial Pathogenesis (chairs: Jorge E. Galan, Yale, and Jorge Benach, Stony Book). Biotechnology and pharmaceutical collaborators are represented in the Diagnostics and Pathogen Discovery (Agilent, Akonni, Cepheid, Xynostics, 454 Life Sciences), Therapeutics (Prosetta, Snowdon), and Passive Immunotherapeutics (Regeneron) themes. These industrial links provide not only intellectual capital and resources but also a path for moving discoveries from NBC laboratories to a larger arena where they can contribute to human health and welfare. Additional strength derives from relationships with national and international public health agencies that provide unique access to insights and clinical materials (such as diagnostic samples and PBMC) that enable work that could not otherwise be pursuec. Core facilities will include Protein Expression, Animal Models, and Proteomics. We will also invest in Developmental Projects (innovative pilot projects) and in Career Development and Training Programs that include individual and group career development awards. As a Center based in a School of Public Health and a State Department of Health, the NBC has a firm commitment to and practical understanding of Emergency Preparedness.

Public Health Relevance

A major hub for trade, tourism and immigration, and center for diplomacy, entertainment and finance, NYC is particularly vulnerable to emerging infectious diseases (EID) and bioterrorism. The greater NYC metro area comprises extraordinary biomedical resources and expertise. Motivated by the events of 9/11, the regional biomedical research community crystallized its efforts in addressing the challenges of biodefense and EID by establishing the NBC, an inter-institutional program focused on research and training initiatives.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-DDS-M (J1))
Program Officer
Schaefer, Michael R
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Columbia University (N.Y.)
Public Health & Prev Medicine
Schools of Public Health
New York
United States
Zip Code
Johnson, Joshua C; Martinez, Osvaldo; Honko, Anna N et al. (2014) Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells. Antiviral Res 107:102-9
Gough, Daniel J; MariƩ, Isabelle J; Lobry, Camille et al. (2014) STAT3 supports experimental K-RasG12D-induced murine myeloproliferative neoplasms dependent on serine phosphorylation. Blood 124:2252-61
Kazakov, Teymur; Kuznedelov, Konstantin; Semenova, Ekaterina et al. (2014) The RimL transacetylase provides resistance to translation inhibitor microcin C. J Bacteriol 196:3377-85
Rajsbaum, Ricardo; Garcia-Sastre, Adolfo; Versteeg, Gijs A (2014) TRIMmunity: the roles of the TRIM E3-ubiquitin ligase family in innate antiviral immunity. J Mol Biol 426:1265-84
Lo, Michael K; Bird, Brian H; Chattopadhyay, Anasuya et al. (2014) Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters. Antiviral Res 101:26-9
Mackow, Erich R; Dalrymple, Nadine A; Cimica, Velasco et al. (2014) Hantavirus interferon regulation and virulence determinants. Virus Res 187:65-71
Varshney, Avanish K; Wang, Xiaobo; Aguilar, Jorge L et al. (2014) Isotype switching increases efficacy of antibody protection against staphylococcal enterotoxin B-induced lethal shock and Staphylococcus aureus sepsis in mice. MBio 5:e01007-14
Chung, Lawton K; Philip, Naomi H; Schmidt, Valentina A et al. (2014) IQGAP1 is important for activation of caspase-1 in macrophages and is targeted by Yersinia pestis type III effector YopM. MBio 5:e01402-14
DiLillo, David J; Tan, Gene S; Palese, Peter et al. (2014) Broadly neutralizing hemagglutinin stalk-specific antibodies require Fc?R interactions for protection against influenza virus in vivo. Nat Med 20:143-51
Szaba, Frank M; Kummer, Lawrence W; Duso, Debra K et al. (2014) TNF? and IFN? but not perforin are critical for CD8 T cell-mediated protection against pulmonary Yersinia pestis infection. PLoS Pathog 10:e1004142

Showing the most recent 10 out of 549 publications